Advances in the Treatment of Immune Thrombocytopenia: Strategies for Optimizing Clinical and Patient Outcomes | PTCE Pharmacy Connect

Educational Objectives

• Outline current guideline recommendations and strategies pharmacists can implement for the management of immune thrombocytopenia (ITP)

• Recall the efficacy and safety of emerging agents for the treatment of ITP

 

Moderator:

Anthony J. Perissinotti, PharmD, BCOP

To claim CE credit for this activity, please visit the link below:

https://www.pharmacytimes.org/courses/advances-in-the-treatment-of-immune-thrombocytopenia-strategies-for-optimizing-clinical-and-patient-outcomes

Hematology Clinical Pharmacist Specialist

Clinical Team Leader Hematology/Oncology

Adjunct Clinical Assistant Professor

University of Michigan – Michigan Medicine

Ann Arbor, Michigan

 

Faculty:

Lisa Charneski, PharmD, BCPS

Assistant Dean for Academic Affairs

Philadelphia College of Pharmacy

Associate Professor of Clinical Pharmacy

Department of Pharmacy Practice Saint Joseph’s University

Philadelphia, Pennsylvania

Anthony J. Perissinotti, PharmD, BCOP has the following relevant financial relationships with commercial interests to disclose:
Consultant: AbbVie, BeiGene, Janssen

Lisa Charneski, PharmD, BCPS, has no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Karleen Melody, PharmD; Crissy Wilson; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (0.1 CEU) under the ACPE universal activity number 0290-0000-22-608-H01-P. The activity is available for CE credit through December 19, 2023.

 

This activity is supported by an educational grant from Rigel Pharmaceuticals, Inc.